The involvement of cardiovascular disease in cancer onset and development represents a
contemporary interest in basic science. It has been recognized, from the most recent …

Oncogenic driver mutations have implications that extend beyond cancer cells themselves.
Aberrant tumour cell signalling has various effects on the tumour microenvironment and anti …

Mutational activation of KRAS occurs commonly in lung carcinogenesis and, with the recent
US Food and Drug Administration approval of covalent inhibitors of KRAS G12C such as …

The development of immune checkpoint blockade (ICB) therapies has been instrumental in
advancing the field of immunotherapy. Despite the prominence of these treatments, many …

There are two major groups of lung cancer: non-small cell lung cancer (NSCLC) and small
cell lung cancer (SCLC). NSCLCs can be further separated into three different categories …

Non-small-cell lung cancer (NSCLC) with concurrent mutations in KRAS and the tumour
suppressor LKB1 (KL NSCLC) is refractory to most therapies and has one of the worst …

Immune checkpoint inhibitors (ICIs) have dramatically improved the outcomes of non-small
cell lung cancer patients and have increased the possibility of long-term survival. However …

The Kirsten rat sarcoma viral oncogene homolog (KRAS) and serine/threonine kinase 11
(STK11) co-mutations are associated with the diverse phenotypic and heterogeneous …

Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and is a fast
progressive disease when left untreated. Identification of potential biomarkers in NSCLC is …

LKB1 (liver kinase B1) is a master regulator of several processes such as metabolism,
proliferation, cell polarity and immunity. About one third of non-small cell lung cancers …